March 11, 2019
Tecentriq combination fast approval for PD-L1-positive, metastatic triple-negative breast cancer
Roche said Monday it got accelerated approval to Tecentriq plus chemotherapy for the treatment of adults with unresectable triple-negative breast cancer (TNBC) in people whose tumours express PD-L1, as determined by an FDA-approved test.